1 Serhan, C.N., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21 (2007), 325–332.
2 Bieber, T., Atopic dermatitis. N. Engl. J. Med. 358 (2008), 1483–1494.
3 Spergel, J.M., Paller, A.S., Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 112:6 Suppl. (2003), 118–127.
4 Ong, P.Y., New insights in the pathogenesis of atopic dermatitis. Pediatr. Res. 75 (2014), 171–175.
5 Imokawa, G., Lipid abnormalities in atopic dermatitis. J. Am. Acad. Dermatol. 45:1 Suppl. (2001), 29–32.
6 D'Auria, E., et al. Atopic dermatitis: recent insight on pathogenesis and novel therapeutic target. Asian Pac. J. Allergy Immunol. 34 (2016), 98–108.
7 Arkwright, P.D., et al. Management of difficult-to-treat atopic dermatitis. J. Allergy Clin. Immunol. Pract. 1 (2013), 142–151.
8 Ashcroft, D.M., et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ, 330, 2005, 516.
9 Denby, K.S., Beck, L.A., Update on systemic therapies for atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 12 (2012), 421–426.
10 Akdis, C.A., Therapies for allergic inflammation: refining strategies to induce tolerance. Nat. Med. 18 (2012), 736–749.
11 Wechsler, M.E., et al. Novel targeted therapies for eosinophilic disorders. J. Allergy Clin. Immunol. 130 (2012), 563–571.
12 Legrand, F., Klion, A.D., Biologic therapies targeting eosinophils: current status and future prospects. J. Allergy Clin. Immunol. Pract. 3 (2015), 167–174.
13 Montes-Torres, A., et al. Biological treatments in atopic dermatitis. J. Clin. Med. 4 (2015), 593–613.
14 Guttman-Yassky, E., et al. New era of biologic therapeutics in atopic dermatitis. Expert Opin. Biol. Ther. 13 (2013), 549–561.
15 Zlotnik, A., Yoshie, O., Chemokines: a new classification system and their role in immunity. Immunity 12 (2000), 121–127.
16 Homey, B., et al. Cytokines and chemokines orchestrate atopic skin inflammation. J. Allergy Clin. Immunol. 118 (2006), 178–189.
17 Yoshie, O., Matsushima, K., CCR4 and its ligands: from bench to bedside. Int. Immunol. 27 (2015), 11–20.
18 Panina-Bordignon, P., et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J. Clin. Invest. 107 (2001), 1357–1364.
19 Homey, B., et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 8 (2002), 157–165.
20 Qu, C., et al. Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J. Exp. Med. 200 (2004), 1231–1241.
21 Ma, W., et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J. Clin. Invest. 109 (2002), 621–628.
22 Ouwehand, K., et al. CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis. Eur. J. Immunol. 38 (2008), 3050–3059.
23 Jin, H., et al. Animal models of atopic dermatitis. J. Invest. Dermatol. 129 (2009), 31–40.
24 Schuh, J.M., et al. Airway hyperresponsiveness, but not airway remodeling, is attenuated during chronic pulmonary allergic responses to Aspergillus in CCR4−/− mice. FASEB J. 16 (2002), 1313–1315.
25 Mikhak, Z., et al. Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation. J. Allergy Clin. Immunol. 123 (2009), 67–73.
26 Lehtimaki, S., et al. Absence of CCR4 exacerbates skin inflammation in an oxazolone-induced contact hypersensitivity model. J. Invest. Dermatol. 130 (2010), 2743–2751.
27 Reiss, Y., et al. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med. 194 (2001), 1541–1547.
28 Mirshahpanah, P., et al. CCR4 and CCR10 ligands play additive roles in mouse contact hypersensitivity. Exp. Dermatol. 17 (2008), 30–34.
29 Gombert, M., et al. CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J. Immunol. 174 (2005), 5082–5091.
30 Goya, I., et al. Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. J. Immunol. 170 (2003), 2138–2146.
31 Takabatake, Y., et al. The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. J. Am. Soc. Nephrol. 20 (2009), 1714–1723.
32 Horuk, R., Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 8 (2009), 23–33.
33 Chen, H., et al. CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2. Int. J. Clin. Exp. Pathol. 8 (2015), 6700–6707.
34 Perros, F., et al. Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. Allergy 64 (2009), 995–1002.
35 Conroy, D.M., et al. CCR4 blockade does not inhibit allergic airways inflammation. J. Leukoc. Biol. 74 (2003), 558–563.
36 Ishii, T., et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin. Cancer Res. 16 (2010), 1520–1531.
37 Canavese, M., et al. Therapeutic efficacy and immunological response of CCL5 antagonists in models of contact skin reaction. PLoS ONE, 5, 2010, e8725.
38 Willems, L.I., Ijzerman, A.P., Small molecule antagonists for chemokine CCR3 receptors. Med. Res. Rev. 30 (2010), 778–817.
39 Neighbour, H., et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin. Exp. Allergy 44 (2014), 508–516.
40 Cahn, A., et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. BMC Pharmacol. Toxicol., 14, 2013, 14.
41 Gauvreau, G.M., et al. Dose–response effects of TPI ASM8 in asthmatics after allergen. Allergy 66 (2011), 1242–1248.
42 Imaoka, H., et al. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin. Exp. Allergy 41 (2011), 1740–1746.
43 Pease, J.E., Targeting chemokine receptors in allergic disease. Biochem. J. 434 (2011), 11–24.
44 Galzi, J.L., et al. Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications. Pharmacol. Ther. 126 (2010), 39–55.
45 Blanchetot, C., et al. Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function. J. Biol. Chem. 288 (2013), 25173–25182.
46 Hoellenriegel, J., et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123 (2014), 1032–1039.
47 Borroni, E.M., et al. The chemoattractant decoy receptor D6 as a negative regulator of inflammatory responses. Biochem. Soc. Trans. 34 (2006), 1014–1017.
48 Bonecchi, R., et al. Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J. Immunol. 172 (2004), 4972–4976.
49 Hachet-Haas, M., et al. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J. Biol. Chem. 283 (2008), 23189–23199.
50 Abboud, D., et al. A strategy to discover decoy chemokine ligands with an anti-inflammatory activity. Sci. Rep., 5, 2015, 14746.
51 Stutte, S., et al. Requirement of CCL17 for CCR7- and CXCR4-dependent migration of cutaneous dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 8736–8741.
52 Deruaz, M., et al. Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models. FEBS J. 280 (2013), 4876–4887.
53 Culley, F.J., et al. Proteoglycans are potent modulators of the biological responses of eosinophils to chemokines. Eur. J. Immunol. 33 (2003), 1302–1310.
54 Kawasaki, S., et al. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J. Immunol. 166 (2001), 2055–2062.
55 Santulli-Marotto, S., et al. CCL22-specific antibodies reveal that engagement of two distinct binding domains on CCL22 is required for CCR4-mediated function. Monoclon. Antib. Immunodiagn. Immunother. 34 (2015), 373–380.
56 Santulli-Marotto, S., et al. Surrogate antibodies that specifically bind and neutralize CCL17 but not CCL22. Monoclon. Antib. Immunodiagn. Immunother. 32 (2013), 162–171.
57 Santulli-Marotto, S., et al. Engagement of two distinct binding domains on CCL17 is required for signaling through CCR4 and establishment of localized inflammatory conditions in the lung. PLOS ONE, 8, 2013, e81465.
58 Hudak, S., et al. Immune surveillance and effector functions of CCR10(+) skin homing T cells. J. Immunol. 169 (2002), 1189–1196.
59 Ajram, L., et al. Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists. Eur. J. Pharmacol. 729 (2014), 75–85.
60 Viney, J.M., et al. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy. J. Immunol. 192 (2014), 3419–3427.
